Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background and Purpose—: Recently, plasma soluble urokinase plasminogen activator receptor (suPAR) has gained interest as a marker of cardiovascular risk. suPAR is released through the cleavage of urokinase plasminogen activator receptor (uPAR), which is found in monocytes, activated T-lymphocytes and endothelial cells, all involved in atherosclerosis. suPAR levels have been well studied in plasma, but no studies have focused on suPAR in human atherosclerotic plaques. The aim of this study was to determine whether suPAR measured in the plaque is associated with symptomatic plaques and plaque inflammation. Methods—: Plasma and carotid plaques from 162 patients were analyzed. Lipids, collagen, uPAR, and macrophages were measured histologically. Cytokines and suPAR were measured in homogenized plaque extracts using multiplex immunoassay and ELISA, respectively. Plasma levels of suPAR were analysed with ELISA. CD3, CD4, as well as uPAR mRNA expression were assessed with quantitative real-time polymerase chain reaction in plaque homogenates from 123 patients. Results—: Plaque and plasma suPAR levels were higher in symptomatic patients compared with asymptomatic patients. Plaque suPAR levels correlated with plaque content of lipids and macrophages and with proinflammatory chemokines and cytokines monocyte chemoattractant protein 1, tumor necrosis factor α, interleukin 1β, interleukin 6, platelet-derived growth factor AB/BB, monocyte inflammatory protein 1β, regulated on activation normal T-cell expressed and secreted, and s-CD40L. uPAR mRNA and histological staining for uPAR correlated with plaque content of suPAR. Conclusion—: This study shows that suPAR in human carotid plaques and plasma is associated with the presence of symptoms and that plaque suPAR is associated with the vulnerable inflammatory plaque. These findings strengthen the hypothesis of suPAR as a future marker of vulnerable atherosclerotic plaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019 · cited 1×
“3305 Atherosclerosis is considered an inflammatory disease, initiated by the retention of low-density lipoprotein (LDL) in the arterial subendothelial space.(1) LDL particles, trapped in the vessel wall, undergo modification and induce activation of endothelial cells and recruitment of inflammatory cells through chemo…”
BackgroundInflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Cited by
Pedersen, L. R., Olsen, R. H., Anholm, C., Astrup, A., Eugen-Olsen, J., Fenger, M., Simonsen, L., Walzem, R. L., Haugaard, S. B., & Prescott, E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0934-x · Cited by 98
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97
Yang, A., Dai, J., Xie, Z., Colman, R. W., Wu, Q., Birge, R. B., & Wu, Y. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302590 · Cited by 30
Olson, N. C., Raffield, L. M., Moxley, A. H., Miller-Fleming, T. W., Auer, P. L., Franceschini, N., Ngo, D., Thornton, T. A., Lange, E. M., Li, Y., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.121.003421 · Cited by 16
Metadata
- Authors
- Edsfeldt, A., Nitulescu, M., Grufman, H., Grönberg, C., Persson, A., Nilsson, M., Persson, M., Björkbacka, H., & Gonçalves, I.
- Venue
- Stroke
- Published
- 2012-12
- Volume
- 43
- Issue
- 12
- Pages
- 3305-3312
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2165712147
- Cited by
- 102
- References
- 2
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.